MicroRNA-320 inhibits invasion and induces apoptosis by targeting CRKL and inhibiting ERK and AKT signaling in gastric cancer cells

References

• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• ShresthaSHsuSDHuangWYA systematic review of microRNA expression profiling studies in human gastric cancerCancer Med20143487888824902858
   PubMed Web of Science ®Google Scholar
• WangJLHuYKongXCandidate microRNA biomarkers in human gastric cancer: a systematic review and validation studyPLoS One201389e7368324040025
   PubMed Web of Science ®Google Scholar
• LuJGetzGMiskaEAMicroRNA expression profiles classify human cancersNature2005435704383483815944708
   PubMed Web of Science ®Google Scholar
• TakamizawaJKonishiHYanagisawaKReduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survivalCancer Res200464113753375615172979
   PubMed Web of Science ®Google Scholar
• HsiehISChangKCTsaiYTMicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by down-regulating the Wnt/beta-catenin signaling pathwayCarcinogenesis201334353053823188675
   PubMedGoogle Scholar
• WanLYDengJXiangXJmiR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1Biochem Biophys Res Commun2015457212513225446103
   PubMed Web of Science ®Google Scholar
• SunJYXiaoWZWangFMicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1Mol Med Rep20151222355235925901521
   PubMedGoogle Scholar
• SainiSMajidSYamamuraSRegulatory role of mir-203 in prostate cancer progression and metastasisClin Cancer Res201117165287529821159887
   PubMed Web of Science ®Google Scholar
• EadesGYangMYaoYZhangYZhouQmiR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cellsJ Biol Chem201128647407254073321926171
   PubMed Web of Science ®Google Scholar
• MateescuBBatistaLCardonMmiR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress responseNat Med201117121627163522101765
   PubMed Web of Science ®Google Scholar
• BorralhoPMSimoesAEGomesSEmiR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferationPLoS One201168e2378721901135
   PubMedGoogle Scholar
• SatoSKatsushimaKShinjoKHistone deacetylase inhibition in prostate cancer triggers miR-320-Mediated suppression of the androgen receptorCancer Res201676144192420427216188
   PubMedGoogle Scholar
• WuYYChenYLJaoYCHsiehISChangKCHongTMmiR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1Angiogenesis201417124726024114198
   PubMed Web of Science ®Google Scholar
• ChengCChenZQShiXTMicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthaseTumour Biol20143554177418324390663
   PubMedGoogle Scholar
• KnudsenKEDiehlJAHaimanCAKnudsenESCyclin D1: polymorphism, aberrant splicing and cancer riskOncogene200625111620162816550162
   PubMed Web of Science ®Google Scholar
• RatschillerDHeighwayJGuggerMCyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survivalJ Clin Oncol200321112085209312775733
   PubMedGoogle Scholar
• RoyPGThompsonAMCyclin D1 and breast cancerBreast200615671872716675218
   PubMed Web of Science ®Google Scholar
• KeumJSKongGYangSCCyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancerBr J Cancer199981112713210487623
   PubMedGoogle Scholar
• IizasaTFujisawaTSuzukiMElevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patientsClin Cancer Res1999511491539918213
   PubMed Web of Science ®Google Scholar
• ShiragaMYanoSYamamotoAOrgan heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell linesCancer Res200262205967597312384564
   PubMedGoogle Scholar
• YlisirnioSHoyhtyaMTurpeenniemi-HujanenTSerum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer – TIMP-1 as a prognostic markerAnticancer Res2000202B1311131610810441
   PubMedGoogle Scholar
• DongQZWangYTangZPDerlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9Am J Pathol2013182395496423306155
   PubMed Web of Science ®Google Scholar
• ChengSPYinPHHsuYCLeptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathwaysOncol Rep20112651265127121750869
   PubMedGoogle Scholar
• HanZHongLHanYPhospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and BaxJ Exp Clin Cancer Res200726226126817725107
   PubMed Web of Science ®Google Scholar
• ten HoeveJMorrisCHeisterkampNGroffenJIsolation and chromosomal localization of CRKL, a human crk-like geneOncogene199389246924748361759
   PubMedGoogle Scholar
• FellerSMCrk family adaptors-signalling complex formation and biological rolesOncogene200120446348637111607838
   PubMed Web of Science ®Google Scholar
• ten HoeveJArlinghausRBGuoJQHeisterkampNGroffenJTyrosine phosphorylation of CRKL in Philadelphia+ leukemiaBlood1994846173117367521685
   PubMedGoogle Scholar
• ten HoeveJKaartinenVFioretosTCellular interactions of CRKL, and SH2-SH3 adaptor proteinCancer Res19945410256325678168080
   PubMedGoogle Scholar
• SenechalKHalpernJSawyersCLThe CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogeneJ Biol Chem19962713823255232618798523
   PubMedGoogle Scholar
• HemmeryckxBvan WijkAReichertACrkl enhances leukemogenesis in BCR/ABL P190 transgenic miceCancer Res20016141398140511245441
   PubMedGoogle Scholar
• WangYDongQZFuLStoeckerMWangEWangEHOverexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancerMol Carcinog2013521189089922753141
   PubMedGoogle Scholar
• LadanyiMCRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be?Cancer Discov20111756056122211192
   PubMedGoogle Scholar